The PI3K/AKT/mTOR signaling pathway is frequently altered in BC, mostly from the HR+ subtype [12,153,198], being associated with tumor development, disease progression and therapy resistance, as recently reviewed [199]. This evidence concerns the gene MTOR and breast cancer.